This site is intended for UK healthcare professionals only

Prescribing information for Rybelsus®▼ (Semaglutide tablets), Ozempic®▼ (semaglutide) and Victoza®(liraglutide) can be accessed by clicking the relevant button below

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Stores. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.
This promotional symposium has been developed, organised and funded by Novo Nordisk for UK healthcare professionals only.
Novo Nordisk products will be discussed.

On-demand video

Type 2 diabetes and cardiovascular disease: An evidence-based discussion on semaglutide in adults living with Type 2 diabetes.

This promotional video presentation was originally broadcast on 26th May 2022.

Please note that the speaker(s) are not able to answer questions from attendees watching the video on-demand.


By clicking any of the links below you will be going to the Novo Nordisk website which will have promotional material

Register for optional consent to receive communication for Novo Nordisk UK

Novo Nordisk HCP Portal

Ozempic microsite

Rybelsus microsite

Novo Nordisk HCP Portal

Ozempic microsite

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut

Company profile

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.
Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.

UK22RYB00132 | May 2022

© Copyright Omniamed Communications. All Rights Reserved 108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom